Jefferies Global Healthcare Conference
Logotype for Kodiak Sciences Inc

Kodiak Sciences (KOD) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Kodiak Sciences Inc

Jefferies Global Healthcare Conference summary

16 Nov, 2026

Pipeline and DAYBREAK results

  • Retina-focused pipeline includes three late-stage assets: tarcocimab (Zenkuda), KSI-101 and KSI-501.

  • GLOW2 reported strong, safe-looking Phase III results in diabetic retinopathy in March, using the commercial formulation.

  • In DAYBREAK, Zenkuda showed rapid effect versus EYLEA and sustained vision gains; more than half of patients reached six-month dosing under sensitive retreatment criteria.

  • 48% reached six-month dosing after loading; six months was the protocol cap, and management said more than half did not meet retreatment criteria at the cap.

  • Management said patient durability varies substantially; year-two intervals may shorten for some patients and lengthen for others.

Zenkuda filing and commercialization

  • A multi-indication BLA for wet AMD, retinal vein occlusion and diabetic retinopathy was targeted before year-end 2026; management said the filing was on track and FDA had agreed to the combined filing and formulation bridge.

  • Management described remaining BLA work as assembly and filing, with no fundamental unknowns.

  • The hoped-for label would be straightforward and reflect the commercial formulation; management advocated flexible dosing, potentially Q4–Q24 in wet AMD and a broad interval range in RVO and DR.

  • Management positioned Zenkuda as a potential option across patients, aiming to extend existing dosing intervals while retaining rapid effect; market share and pricing remained uncertain.

  • Approval was projected by year-end 2027, subject to regulatory review.

KSI-101 and MESI program

  • KSI-101 targets inflammatory macular edema (MESI); PEAK 1 was fully enrolled, with top-line results expected before Christmas 2026, and the pivotal program also includes PEAK 2 and PINNACLE.

  • PEAK 2 and PINNACLE top-line data were anticipated in May–June 2027; a filing could follow PEAK 1 alone as early as April, or use PEAK 1 safety data plus the other studies’ primary endpoints around mid-2027.

  • Management described the MESI population as broad, including severely affected, uveitic and refractory postsurgical patients, and said the label population should reflect those studied.

  • KSI-101’s pivotal studies compare against sham; approval was projected for early 2028.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Kodiak Sciences